Multinational phase 2 study of cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcoma

Treatment options for patients with unresectable and/or metastatic dedifferentiated liposarcoma (DDLPS) are limited. New drugs are required. A multinational phase 2 study by the EORTC Soft Tissue and Bone Sarcoma Group evaluated cabazitaxel in these patients. The trial met its primary end point, with 21 of 38 patients (55%) being progression-free at 12 weeks. The authors conclude that a phase 3 study of cabazitaxel for metastatic or inoperable locally advanced DDLPS is warranted.